A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies

References

• Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, . Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–100.
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, . Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331:44–9.
   PubMed Web of Science ®Google Scholar
• Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood. 2011;117:764–71.
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, . Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333–9.
   PubMed Web of Science ®Google Scholar
• Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, . Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102:814–9.
   PubMed Web of Science ®Google Scholar
• Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, . Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105:4878–84.
   PubMed Web of Science ®Google Scholar
• Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, . Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116:2411–9.
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, . Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in cancer patients. Blood. 2005;105:3051–7.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, . NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28:955–9.
   PubMed Web of Science ®Google Scholar
• Stringaris K, Adams S, Uribe M, Eniafe R, Wu CO, Savani BN, . Donor KIR genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant. 2010;16:1257–64.
   Google Scholar
• Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, . Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004;172:644–50.
   PubMed Web of Science ®Google Scholar
• Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, . Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood. 2009;113:3119–29.
   PubMed Web of Science ®Google Scholar
• Pfeiffer MM, Feuchtinger T, Teltschik HM, Schumm M, Muller I, Handgretinger R, . Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children. Haematologica. 2010;95: 1381–8.
   Google Scholar
• Cifaldi L, Lo ME, Forloni M, Giorda E, Lorenzi S, Petrini S, . Natural killer cells efficiently reject lymphoma silenced for the endoplasmic reticulum aminopeptidase associated with antigen processing. Cancer Res. 2011;71:1597–606.
   PubMed Web of Science ®Google Scholar
• Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106: 376–83.
   PubMed Web of Science ®Google Scholar
• Manabe A, Coustan-Smith E, Kumagai M, Behm FG, Raimondi SC, Pui CH, . Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia. Blood. 1994;83:1731–7.
   PubMed Web of Science ®Google Scholar
• Harmon JM, Norman MR, Fowlkes BJ, Thompson EB. Dexamethasone induces irreversible G1 arrest and death of a human lymphoid cell line. J Cell Physiol. 1979;98:267–78.
   PubMed Web of Science ®Google Scholar
• Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, . Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69:4010–7.
   PubMed Web of Science ®Google Scholar
• Fujisaki H, Kakuda H, Imai C, Mullighan CG, Campana D. Replicative potential of human natural killer cells. Br J Haematol. 2009;69:4010–7.
   Google Scholar
• Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res. 2010;16:3901–9.
   PubMed Web of Science ®Google Scholar
• Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Campana D. Chimeric receptors with 4 - 1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18:676–84.
   PubMed Web of Science ®Google Scholar
• Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni J, . Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther. 2010;17:147–54.
   PubMed Web of Science ®Google Scholar
• Mihara K, Imai C, Coustan-Smith E, Dome JS, Dominici M, Vanin E, . Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol. 2003;120: 846–9.
   PubMed Web of Science ®Google Scholar
• Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4 - 1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4 - 1BB monoclonal antibodies. Cell Immunol. 1998;190:167–72.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, . CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117:2423–32.
   PubMed Web of Science ®Google Scholar
• Kustikova O, Brugman M, Baum C. The genomic risk of somatic gene therapy. Semin Cancer Biol. 2010;20:269–78.
   Google Scholar
• Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3: 35–45.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299–308.
   PubMed Web of Science ®Google Scholar
• June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol. 2009;9: 704–16.
   Google Scholar
• Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Curr Opin Immunol. 2010;22:251–7.
   PubMedGoogle Scholar
• Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–33.
   PubMed Web of Science ®Google Scholar
• Rabinovich PM, Komarovskaya ME, Ye ZJ, Imai C, Campana D, Bahceci E, . Synthetic messenger RNA as a tool for gene therapy. Hum Gene Ther. 2006;17:1027–35.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, . Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010;70:9053–61.
   PubMed Web of Science ®Google Scholar
• Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, . Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010; 70:9554–61.
   PubMed Web of Science ®Google Scholar
• Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, . Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360:2730–41.
   PubMed Web of Science ®Google Scholar
• Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, . Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010;116:1165–76.
   PubMed Web of Science ®Google Scholar
• Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol. 2011;29:544–50.
   PubMed Web of Science ®Google Scholar
• Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med. 2008;168:469–76.
   PubMed Web of Science ®Google Scholar
• Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods. 2000;243:59–75.
   PubMed Web of Science ®Google Scholar